Pulnovo has treated the first two US patients in PULSE-LHD, a randomized 750-patient IDE study testing whether pulmonary artery denervation can reduce major heart-failure events in combined pre- and post-capillary pulmonary hypertension.
HBM7004 can now enter clinical development in both China and the United States after NMPA and FDA IND clearances, putting Harbour BioMed’s B7H4-dependent T-cell engager into its first human test.
Keenova has dosed the first patient in a randomized Phase 3 study evaluating whether collagenase injections can reduce fixed toe contracture and provide a nonsurgical treatment for hammer toe.
Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
Cutiva PLUS has completed its first patient cases after Resivant scaled its crosslinked silicone-cyanoacrylate adhesive, moving a 2024-cleared wound-closure system toward broader commercial use.
West Cancer Center has received IRB approval to join IceCure’s 400-patient ChoICE post-market study of ProSense in women aged 70 and older with small, biologically low-risk breast cancers.
Lupin’s VISUfarma will handle YUVEZZI regulation and commercialization across the EU, UK and selected European markets, while Tenpoint receives an investment, milestones and tiered royalties.
CureGene has dosed the first participant in a randomized Phase 1 study of CG-0416, an oral liver-targeted THR-β prodrug whose weight-loss and muscle-preservation claims remain based on preclinical evidence.
Most FDA-cleared surgical robots still operate under direct human control, while research systems are beginning to automate individual tasks. Moving from task automation to independent surgery requires solving perception, tissue variability, failure recovery and liability.
Therapeutic RNA editing recruits naturally occurring enzymes to rewrite individual RNA letters without permanently changing genomic DNA, trading lifetime correction for reversibility and potentially simpler risk management.